Skip to main content
. 2023 May 6;37(5):675–684. doi: 10.1007/s40259-023-00601-w

Fig. 2.

Fig. 2

Prevalence of use every 2 weeks of mAbs/antivirals as a whole for early treatment of COVID-19 outpatients based on the distribution of specific SARS-CoV-2 variants in England and Italy from December 2021 to October 2022. mAbs monoclonal antibodies